IMCY-0098 is a peptide immunotherapy based on proinsulin and developed by Imcyse to reduce the progression of type 1 diabetes.[1][2]

IMCY-0098
Legal status
Legal status
  • Investigational
Identifiers
  • H-His-Cys-Pro-Tyr-Cys-Ser-Leu-Gln-Pro-Leu-Ala-Leu-Glu-Gly-Ser-Leu-Gln-Lys-Arg-Gly-NH2
UNII
Chemical and physical data
FormulaC95H157N29O28S2
Molar mass2217.60 g·mol−1

References

edit
  1. ^ Van Rampelbergh, Jean; Achenbach, Peter; Leslie, Richard David; Ali, Mohammad Alhadj; Dayan, Colin; Keymeulen, Bart; Owen, Katharine R.; Kindermans, Martin; Parmentier, Frédéric; Carlier, Vincent; Ahangarani, Roxana R.; Gebruers, Evelien; Bovy, Nicolas; Vanderelst, Luc; Van Mechelen, Marcelle; Vandepapelière, Pierre; Boitard, Christian (24 May 2023). "First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes". BMC Medicine. 21 (1): 190. doi:10.1186/s12916-023-02900-z. ISSN 1741-7015. PMC 10210318. PMID 37226224.
  2. ^ Atkinson, Mark A; Roep, Bart O; Posgai, Amanda; Wheeler, Daniel C S; Peakman, Mark (January 2019). "The challenge of modulating β-cell autoimmunity in type 1 diabetes". The Lancet Diabetes & Endocrinology. 7 (1): 52–64. doi:10.1016/S2213-8587(18)30112-8. PMC 7322790. PMID 30528099.